SEC Pressed Cooper Companies on Non-GAAP Gross Profit, Tax Adjustment
A year-long comment-letter dialogue pushed Cooper Companies to defend and eventually narrow its non-GAAP presentations while adding new segment and disclosure detail.
The Cooper Companies (COO) spent more than a year defending how it presents profit to investors after SEC staff repeatedly challenged the company's non-GAAP gross profit measure, its treatment of a large UK tax benefit, and its labeling of recurring costs as "one-time." The dialogue, which ran from an April 2024 comment letter through a final round that closed in early 2026, forced Cooper to walk back some positions, defend others in detail, and ultimately commit to clearer disclosure across its segment reporting, revenue recognition policies, and non-GAAP reconciliations.
The most persistent friction centered on gross profit. Staff argued that because Cooper's cost of sales excluded amortization of a "composite intangible asset" tied to its Paragard IUD business, the gross profit line on its income statement was not fully GAAP-compliant and that any non-GAAP gross margin needed to reconcile from a fully burdened GAAP figure. Cooper initially proposed relabeling cost of sales and dropping the gross profit subtotal altogether, then reversed course, warning that the change itself could signal to investors that its historic presentation had been wrong. The company ultimately retained the gross profit subtotal, built a full SAB Topic 1:M materiality analysis showing the excluded technology amortization was roughly 1% of revenue, and committed to reconciling non-GAAP gross profit from GAAP going forward.
The other major flashpoint was a $1.99 billion deferred tax asset Cooper booked in fiscal 2021 after transferring CooperVision intellectual property to a UK subsidiary. Staff questioned whether the company's non-GAAP add-back — which reversed the GAAP-required immediate recognition and instead reflected the tax benefit as it was realized through UK amortization — amounted to an individually tailored accounting principle barred under the SEC's non-GAAP guidance. Cooper mounted an extensive defense, citing prior CFO earnings-call disclosures about the transfer and arguing the adjustment tracked actual UK tax law rather than an invented accounting convention. Rather than drop the adjustment, the company agreed only to add explanatory disclosure clarifying the GAAP treatment and the ongoing nature of the benefit.
Staff also pushed on how Cooper characterized recurring charges. After flagging in earlier rounds that costs tied to European medical device regulations, business disruptions, and litigation were being called "one-time" despite recurring across multiple periods, the SEC cited the company's own Compliance and Disclosure Interpretation guidance and asked Cooper to drop the language entirely. Cooper agreed, removing "one-time" from its earnings-release characterizations and from its description of acquisition and integration costs as "exceptional or unusual." It also agreed to expand footnotes so that the individual adjustment categories in its non-GAAP reconciliation — acquisition and integration charges, business exits, business optimization costs, and a catch-all "other" line — actually summed to the totals presented, after staff pointed out they had not.
On revenue recognition, staff pressed Cooper multiple times over service revenue tied to its Generate Life Sciences fertility and stem-cell storage business, asking for a full materiality analysis and detailed ASC 606 disclosures covering performance obligations, timing of recognition, and variable consideration. Cooper maintained that service revenue — under 10% of consolidated revenue and a shrinking share as CooperVision grew — did not warrant expanded disclosure, but it agreed to add plainer language describing how processing, storage, and coordination-service revenue is recognized across its stem cell, sperm, egg, and genomic testing lines.
The most recent exchange, which closed in February 2026, moved beyond non-GAAP mechanics into segment reporting. Staff asked Cooper to explain how its chief operating decision maker actually uses operating income to evaluate segment performance and allocate resources, citing specific ASC 280 guidance. Cooper agreed to add disclosure describing quarterly CODM reviews against forecasts and historical results, starting with its fiscal first-quarter 2026 filing.
Across the full dialogue, Cooper held its ground on the substance of its non-GAAP framework — the gross profit subtotal survived, and the UK tax adjustment remains in the reconciliation — while conceding ground on labeling, footnote granularity, and narrative disclosure. The pattern suggests investors should expect more granular breakdowns in future non-GAAP tables rather than a wholesale change to how Cooper defines its adjusted earnings.